Gaussia luciferase for bioluminescence tumor monitoring in comparison with firefly luciferase

Molecular Imaging

Volumn 10, Issue 5, 2011, Pages 377-385

  Inoue, Yusuke ^a   Sheng, Fugeng ^a   Kiryu, Shigeru ^a   Watanabe, Makoto ^a   Ratanakanit, Harnprasopwat ^a   Izawa, Kiyoko ^a   Tojo, Arinobu ^a   Ohtomo, Kuni ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FIREFLY LUCIFERASE; IN-VIVO; LIVING ANIMALS; TUMOR CELLS; TUMOR MONITORING;

ASSAYS; BIOLUMINESCENCE; BLOOD; MAMMALS; MONITORING; PHOSPHORESCENCE;

TUMORS;

COELENTERAZINE; IMIDAZOLE DERIVATIVE; LUCIFERASE; PYRAZINE DERIVATIVE;

ANIMAL; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN HCT116; COMPARATIVE STUDY; ENZYMOLOGY; EXPERIMENTAL NEOPLASM; GENETICS; HUMAN; KINETICS; METABOLISM; MOUSE; MOUSE MUTANT; NONPARAMETRIC TEST; REPORTER GENE; SPECTROFLUOROMETRY; WHOLE BODY IMAGING;

ANIMALS; AREA UNDER CURVE; GENES, REPORTER; HCT116 CELLS; HUMANS; IMIDAZOLES; KINETICS; LUCIFERASES; MICE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; PYRAZINES; SPECTROMETRY, FLUORESCENCE; STATISTICS, NONPARAMETRIC; WHOLE BODY IMAGING;

EID: 80053008039     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2010.00057     Document Type: Article

References (31)

1. Contag CH, Jenkins D, Contag PR, et al. Use of reporter genes for optical measurements of neoplastic disease in vivo. Neoplasia 2000; 2:41-52, doi:10.1038/sj.neo.7900079. (Pubitemid 30123179)
2. Edinger M, Cao YA, Hornig YS, et al. Advancing animal models of neoplasia through in vivo bioluminescence imaging. Eur J Cancer 2002;38:2128-36, doi:10.1016/S0959-8049(02)00410-0. (Pubitemid 35223250)
3. Paroo Z, Bollinger RA, Braasch DA, et al. Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumour burden. Mol Imaging 2004;3:117-24, doi:10.1162/1535350041464865.
4. Rehemtulla A, Stegman LD, Cardozo SJ, et al. Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia 2000;2:491-5, doi:10.1038/ sj.neo.7900121. (Pubitemid 32098683)
5. Szentirmai O, Baker CH, Lin N, et al. Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumour volume and longitudinal use in assessing tumour growth and antiangiogenic treatment effect. Neurosurgery 2006;58:365-72, doi:10.1227/01.NEU.0000195114.24819.4F. (Pubitemid 43212802)
6. Nyati MK, Symon Z, Kievit E, et al. The potential of 5- fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model. Gene Ther 2002;9:844-9, doi:10.1038/sj.gt.3301706. (Pubitemid 34716328)
7. Smakman N, Martens A, Kranenburg O, et al. Validation of bioluminescence imaging of colorectal liver metastases in the mouse. J Surg Res 2004;122:225-30, doi:10.1016/j.jss.2004.05.021. (Pubitemid 39535947)
8. Mandl SJ, Mari C, Edinger M, et al. Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome. Mol Imaging 2004;3:1-8, doi:10.1162/ 153535004773861679.
9. Jenkins DE, Oei Y, Hornig YS, et al. Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumour growth and metastasis. Clin Exp Metastasis 2003;20:733-44, doi:10.1023/B:CLIN.0000006815.49932.98. (Pubitemid 38019275)
10. Scatena CD, Hepner MA, Oei YA. Imaging of bioluminescent LNCaP-luc-M6 tumours: a new animal model for the study of metastatic human prostate cancer. Prostate 2004;59:292-303, doi:10.1002/pros.20003. (Pubitemid 38509762)
11. Zeamari S, Rumping G, Floot B, et al. In vivo bioluminescence imaging of locally disseminated colon carcinoma in rats. Br J Cancer 2004;90:1259-64, doi:10.1038/sj.bjc.6601637. (Pubitemid 38496822)
12. Inoue Y, Izawa K, Tojo A, et al. Monitoring of disease progression by bioluminescence imaging and magnetic resonance imaging in an animal model of hematologic malignancy. Exp Hematol 2007; 35:407-15, doi:10.1016/j.exphem.2006. 11.006.
13. Inoue Y, Izawa K, Kiryu S, et al. Bioluminescent evaluation of the therapeutic effects of total body irradiation in a murine hematological malignancy model. Exp Hematol 2008;36:1634-41, doi:10.1016/j.exphem.2008.08.004.
14. Bhaumik S, Gambhir SS. Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc Natl Acad Sci U S A 2002;99:377-82, doi:10.1073/pnas.012611099. (Pubitemid 34060369)
15. Tannous BA, Kim DE, Fernandez JL, et al. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther 2005;11:435-43, doi:10.1016/ j.ymthe.2004.10.016. (Pubitemid 40277320)
16. Wurdinger T, Badr C, Pike L, et al. A secreted luciferase for ex vivo monitoring of in vivo processes. Nat Methods 2008;5:171-3, doi:10.1038/nmeth. 1177. (Pubitemid 351181745)
17. Tannous BA. Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. Nat Protoc 2009;4:582-91, doi:10.1038/nprot. 2009.28.
18. Chung E, Yamashita H, Au P, et al. Secreted Gaussia luciferase as a biomarker for monitoring tumour progression and treatment response of systemic metastases. PLoS One 2009;4:e8316, doi:10.1371/journal.pone.0008316.
19. Inoue Y, Tojo A, Sekine R, et al. In vitro validation of bioluminescent monitoring of disease progression and therapeutic response in leukaemia model animals. Eur J Nucl Med Mol Imaging 2006;33:557-65, doi:10.1007/s00259-005-0048- 4.
20. Inoue Y, Kiryu S, Watanabe M, et al. Timing of imaging after Dluciferin injection affects the longitudinal assessment of tumor growth using in vivo bioluminescence imaging. Int J Biomed Imaging 2010;2010:471408, doi:10.1155/2010/471408.
21. Kimura T, Hiraoka K, Kasahara N, et al. Optimization of enzymesubstrate pairing for bioluminescence imaging of gene transfer using Renilla and Gaussia luciferases. J Gene Med 2010;12:528-37, doi:10.1002/jgm.1463.
22. Keyaerts M, Verschueren J, Bos TJ, et al. Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D-luciferin: effect on intensity, time kinetics and repeatability of photon emission. Eur J Nucl Med Mol Imaging 2008;35:999-1007, doi:10.1007/s00259-007- 0664-2.
23. Inoue Y, Kiryu S, Izawa K, et al. Comparison of subcutaneous and intraperitoneal injection of D-luciferin for in vivo bioluminescence imaging. Eur J Nucl Med Mol Imaging 2009;36:771-9, doi:10.1007/ s00259-008-1022-8.
24. Zhao H, Doyle TC, Wong RJ, et al. Characterization of coelenterazine analogs for measurements of Renilla luciferase activity in live cells and living animals. Mol Imaging 2004;3:43-54, doi:10.1162/153535004773861714.
25. Wang W, El-Deiry WS. Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model. Cancer Biol Ther 2003;2:196-202.
26. Sarraf-Yazdi S, Mi J, Dewhirst MW, et al. Use of in vivo bioluminescence imaging to predict hepatic tumour burden in mice. J Surg Res 2004;120:249-55, doi:10.1016/j.jss.2004.03.013. (Pubitemid 38834193)
27. Zhao H, Doyle TC, Coquoz O, et al. Emission spectra of bioluminescent reporters and interaction with mammalian tissue determine the sensitivity of detection in vivo. J Biomed Opt 2005; 10:41210, doi:10.1117/1.2032388. (Pubitemid 43328902)
28. Colby LA, Morenko BJ. Clinical considerations in rodent bioimaging. Comp Med 2004;54:623-30. (Pubitemid 44204197)
29. Hildebrandt IJ, Su H, Weber WA. Anesthesia and other considerations for in vivo imaging of small animals. ILAR J 2008;49:17-26.
30. Maguire CA, Deliolanis NC, Pike L, et al. Gaussia luciferase variant for high-throughput functional screening applications. Anal Chem 2009;81:7102-6, doi:10.1021/ac901234r.
31. Welsh JP, Patel KG, Manthiram K, et al. Multiply mutated Gaussia luciferases provide prolonged and intense bioluminescence. Biochem Biophys Res Commun 2009;389:563-8, doi:10.1016/ j.bbrc.2009.09.006.